Build your own keyword analysis with our tools
SEO Report
Server Infos
Backlinks

HTML Analysis

Page Status
 

Found

Highlighted Content
Title

ABRAXANE.com | Official Site | ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)

Description

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound); indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. WARNING - NEUTROPENIA Do not administer ABRAXANE therapy to patients who have baseline neutrophil counts of less than 1,500 cells/mm3. In order to monitor the occurrence of bone marrow suppression, primarily neutropenia, which may be severe and result in infection, it is recommended that frequent peripheral blood cell counts be performed on all patients receiving ABRAXANE Note: An albumin form of paclitaxel may substantially affect a drug’s functional properties relative to those of drug in solution. DO NOT SUBSTITUTE FOR OR WITH OTHER PACLITAXEL FORMULATIONS CONTRAINDICATIONS Neutrophil Counts ABRAXANE should not be used in patients who have baseline neutrophil counts of <1,500 cells/mm3 Hypersensitivity Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be rechallenged with the drug WARNINGS AND PRECAUTIONS Hematologic Effects Bone marrow suppression (primarily neutropenia) is dose-dependent and a dose-limiting toxicity of ABRAXANE. In clinical studies, Grade 3-4 neutropenia occurred in 34% of patients with metastatic breast cancer (MBC) and 47% of patients with non-small cell lung cancer (NSCLC) Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Day 1 for MBC and Days 1, 8, and 15 for NSCLC Do not administer ABRAXANE to patients with baseline absolute neutrophil counts (ANC) of less than 1,500 cells/mm3 In the case of severe neutropenia (<500 cells/mm3 for 7 days or more) during a course of ABRAXANE therapy, reduce the dose of ABRAXANE in subsequent courses in patients with either MBC or NSCLC In patients with MBC, resume treatment with every-3-week cycles of ABRAXANE after ANC recovers to a level >1,500 cells/mm3 and platelets recover to >100,000 cells/mm3 In patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly ABRAXANE and every-3-week carboplatin after ANC recovers to at least 1,500 cells/mm3 and platelet count of at least 100,000 cells/mm3 on Day 1 or to an ANC of at least 500 cells/mm3 and platelet count of at least 50,000 cells/mm3 on Days 8 or 15 of the cycle Nervous System Sensory neuropathy is dose- and schedule-dependent The occurrence of Grade 1 or 2 sensory neuropathy does not generally require dose modification If ≥ Grade 3 sensory neuropathy develops, treatment should be withheld until resolution to Grade 1 or 2 for MBC or until resolution to ≤ Grade1 for NSCLC followed by a dose reduction for all subsequent courses of ABRAXANE Hypersensitivity Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reported Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be re-challenged with this drug Hepatic Impairment Because the exposure and toxicity of paclitaxel can be increased with hepatic impairment, administration of ABRAXANE in patients with hepatic impairment should be performed with caution The starting dose should be reduced for patients with moderate or severe hepatic impairment Albumin (Human) ABRAXANE contains albumin (human), a derivative of human blood Use in Pregnancy: Pregnancy Category D ABRAXANE can cause fetal harm when administered to a pregnant woman If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus Women of childbearing potential should be advised to avoid becoming pregnant while receiving ABRAXANE Use in Men Men should be advised not to father a child while receiving ABRAXANE ADVERSE REACTIONS Randomized Metastatic Breast Cancer (MBC) Study The most common adverse reactions (≥20%) with single-agent use of ABRAXANE vs. Paclitaxel injection in the MBC study were alopecia (90%, 94%), neutropenia (all cases 80%, 82%; severe 9%, 22%), sensory neuropathy (any symptoms 71%, 56%; severe 10%, 2%), abnormal ECG (all patients 60%, 52%; patients with normal baseline 35%, 30%), fatigue/asthenia (any 47%, 39%; severe 8%, 3%), myalgia/arthralgia (any 44%, 49%; severe 8%, 4%), AST elevation (any 39%, 32%), alkaline phosphatase elevation (any 36%, 31%), anemia (all cases 33%, 25%; severe 1%, <1%), nausea (any 30%, 22%; severe 3%, <1%), diarrhea (any 27%, 15%; severe <1%, 1%) and infections (24%, 20%), respectively Sensory neuropathy was the cause of ABRAXANE discontinuation in 7/229 (3%) patients Other adverse reactions of note with the use of ABRAXANE vs. Paclitaxel injection included vomiting (any 18%, 10%; severe 4%, 1%), fluid retention (any 10%, 8%; severe 0%, <1%); mucositis (any 7%, 6%; severe <1%, 0%), hepatic dysfunction (elevations in bilirubin 7%, 7%), hypersensitivity reactions (any 4%,12%; severe 0%, 2%), thrombocytopenia (any 2%, 3%; severe <1%, neutropenic sepsis (<1%, <1%), and injection site reactions (<1%, 1%), respectively. Dehydration and pyrexia were also reported Renal dysfunction (any 11%, severe 1%) were reported in patients treated with ABRAXANE (n = 229) In all ABRAXANE treated patients (n=366) ocular/visual disturbances were reported (any 13%; severe 1%) Severe cardiovascular events possibly related to single-agent ABRAXANE occurred in approximately 3% of patients and included cardiac ischemia/infarction, chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension Cases of cerebrovascular attacks (strokes) and transient ischemic attacks have been reported Non-Small Cell Lung (NSCLC) Cancer Study Adverse reactions with a difference of ≥2%, Grade 3 or higher, with combination use of ABRAXANE and carboplatin vs. combination use of Paclitaxel injection and carboplatin in NSCLC were anemia (28%, 7%); neutropenia (47%, 58%); thrombocytopenia (18%, 9%), peripheral neuropathy (3%, 12%), and peripheral edema (0%, <1%), respectively Adverse reactions with a difference of ≥5%, Grades 1-4, with combination use of ABRAXANE and carboplatin vs. combination use of Paclitaxel injection and carboplatin in NSCLC were anemia (98%, 91%), neutropenia (85%, 83%), thrombocytopenia (68%, 55%), peripheral neuropathy (48%, 64%), peripheral edema (10%, 4%), and epistaxis (7%, 2%), respectively The most common adverse reactions (≥20%) of ABRAXANE in combination with carboplatin for NSCLC were anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea, and fatigue The most common serious adverse reactions of ABRAXANE in combination with carboplatin for NSCLC were anemia (4%) and pneumonia (3%) The most common adverse reactions resulting in permanent discontinuation of ABRAXANE were neutropenia (3%), thrombocytopenia (3%), and peripheral neuropathy (1%) The most common adverse reactions resulting in dose reduction of ABRAXANE were neutropenia (24%), thrombocytopenia (13%), and anemia (6%) The most common adverse reactions leading to withholding or delay in ABRAXANE dosing were neutropenia (41%), thrombocytopenia (30%), and anemia (16%) The following common (≥10% incidence) adverse reactions were observed at a similar incidence in ABRAXANE plus carboplatin-treated and paclitaxel injection plus carboplatin-treated patients: alopecia 56%, nausea 27%, fatigue 25%, decreased appetite 17%, asthenia 16%, constipation 16%, diarrhea 15%, vomiting 12%, dyspnea 12%, and rash 10% (incidence rates are for the ABRAXANE plus carboplatin treatment group) Post-marketing Experience With ABRAXANE and Other Paclitaxel Formulations Severe and sometimes fatal hypersensitivity reactions have been reported with ABRAXANE. The use of ABRAXANE in patients previously exhibiting hypersensitivity to paclitaxel injection or to human albumin has not been studied There have been reports of congestive heart fail

Keywords

ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), Treatment for Advanced Breast Cancer, Chemotheraphy Treatment for metastatic breast cancer, late stage mBC, Efficacy, Important Safety Information, clinical trial research, adverse events, safety profile, dosing administration, dosing modifications

H1

IMPORTANT SAFETY INFORMATION
IMPORTANT SAFETY INFORMATION

H2

WARNING - NEUTROPENIA
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
Post-marketing Experience With ABRAXANE and Other Paclitaxel Formulations
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS
DOSAGE AND ADMINISTRATION
WARNING - NEUTROPENIA
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
Post-marketing Experience With ABRAXANE and Other Paclitaxel Formulations
DRUG INTERACTIONS
USE IN SPECIFIC POPULATIONS
DOSAGE AND ADMINISTRATION

H3

Neutrophil Counts
Hypersensitivity
Hematologic Effects
Nervous System
Hypersensitivity
Hepatic Impairment
Albumin (Human)
Use in Pregnancy: Pregnancy Category D
Use in Men
Randomized Metastatic Breast Cancer (MBC) Study
Non-Small Cell Lung (NSCLC) Cancer Study
Nursing Mothers
Pediatric
Geriatric
Renal Impairment
Neutrophil Counts
Hypersensitivity
Hematologic Effects
Nervous System
Hypersensitivity
Hepatic Impairment
Albumin (Human)
Use in Pregnancy: Pregnancy Category D
Use in Men
Randomized Metastatic Breast Cancer (MBC) Study
Non-Small Cell Lung (NSCLC) Cancer Study
Nursing Mothers
Pediatric
Geriatric
Renal Impairment

H4

H5

Text Analysis

Cloud of Keywords from all content
High relevance
 

abraxane severe patients cells mm3 mbc neutropenia counts paclitaxel cancer neuropathy reactions nsclc grade sensory dose cell baseline hypersensitivity receiving neutrophil hepatic treatment patient metastatic impairment breast drug 10% human pregnancy therapy pregnant days

Medium relevance
 

reduced albumin recovers monitor 30% elevation 39% occurrence bone recommended advised performed reaction suppression marrow experience blood study 47% adverse non-small 20% resolution including injection cases 22% platelet administer resume every-3-week count subsequent courses toxicity complete suspension carboplatin safety included injectable prior

Low relevance
 

complete suspension carboplatin safety included injectable prior fetus common category starting apprised harm administered woman blood use hazard women reactions randomized avoid abraxane adverse abraxane use child moderate fetal father childbearing single-agent impairment albumin derivative fatigue 15% infections 24% respectively sensory 27% diarrhea anemia 33% 25% nausea discontinuation vomiting bilirubin 12% thrombocytopenia cancel elevations dysfunction 18% fluid retention mucositis 31% 36% 56% abnormal ecg 60% 71% symptoms 90% 94% 80% 82% 52% 35% 49% 32% alkaline phosphatase 44% arthralgia caution asthenia myalgia alopecia dose- mm3 hypersensitivity rechallenged drug warnings contraindications formulations solution substitute precautions hematologic effects 3-4 occurred studies clinical dose-dependent dose-limiting properties functional chemotherapy advanced caregiver combination albumin-bound protein-bound particles healthcare professional peripheral administration frequent infection warning order 34% drug’s withheld grade1 reduction develops modification generally require fatal anaphylactic exposure increased drug hepatic re-challenged myelotoxicity reported patients schedule-dependent abraxane hypersensitivity severe performing absolute cycles frequently nsclc in cycle nervous dosing reduce case permanently doses weekly level mm3 in recover platelets

Very Low relevance
 
fetus common category starting apprised harm administered woman blood use hazard women reactions randomized avoid abraxane adverse abraxane use child moderate fetal father childbearing single-agent impairment albumin derivative fatigue 15% infections 24% respectively sensory 27% diarrhea anemia 33% 25% nausea discontinuation vomiting bilirubin 12% thrombocytopenia cancel elevations dysfunction 18% fluid retention mucositis 31% 36% 56% abnormal ecg 60% 71% symptoms 90% 94% 80% 82% 52% 35% 49% 32% alkaline phosphatase 44% arthralgia caution asthenia myalgia alopecia dose- mm3 hypersensitivity rechallenged drug warnings contraindications formulations solution substitute precautions hematologic effects 3-4 occurred studies clinical dose-dependent dose-limiting properties functional chemotherapy advanced caregiver combination albumin-bound protein-bound particles healthcare professional peripheral administration frequent infection warning order 34% drug’s withheld grade1 reduction develops modification generally require fatal anaphylactic exposure increased drug hepatic re-challenged myelotoxicity reported patients schedule-dependent abraxane hypersensitivity severe performing absolute cycles frequently nsclc in cycle nervous dosing reduce case permanently doses weekly level mm3 in recover platelets corporation celgene responsibility linked sole control provider proceed fields share loading content okcancel return third-party website click official endorse clinically first-line contraindicated anthracycline locally candidates radiation surgery curative adjuvant months contact expand leaving prescribing failure relapse disease com the

Highlighted Content Analysis

Cloud of Keywords from all content
High relevance
 

abraxane severe patients reactions neutropenia paclitaxel adverse nsclc hypersensitivity < cells mm3 mbc neuropathy cancer impairment carboplatin counts study common peripheral injection anemia thrombocytopenia hepatic 500 drug pregnancy combination neutrophil 10% human &ge albumin reported cell metastatic sensory grade treatment breast dose experience

Medium relevance
 

receiving non-small baseline formulations 12% nausea 30% fatigue randomized category administration 000 nervous pregnant effects cases alopecia days 20% 47% contraindications warning renal 16% blood incidence post-marketing hematologic edema precautions warnings

Low relevance
 

nausea 30% fatigue randomized category administration 000 nervous pregnant effects cases alopecia days 20% 47% contraindications warning renal 16% blood incidence post-marketing hematologic edema precautions warnings carboplatin-treated attacks patient difference interactions resolution mothers pediatric geriatric nursing reduction pulmonary populations dosage fatal safety treated 27% 15% 24% diarrhea asthenia 25% elevation 39% discontinuation 229 single-agent dysfunction 13% 18% vomiting included 56% 22% cardiac advised courses subsequent dosing occurred resume every-3-week > recovers chemotherapy administer therapy recommended bone suppression marrow occurrence performed toxicity reaction monitor albumin-bound including protein-bound 100 particles count platelet injectable suspension reduced

Very Low relevance
 
carboplatin-treated attacks patient difference interactions resolution mothers pediatric geriatric nursing reduction pulmonary populations dosage fatal safety treated 27% 15% 24% diarrhea asthenia 25% elevation 39% discontinuation 229 single-agent dysfunction 13% 18% vomiting included 56% 22% cardiac advised courses subsequent dosing occurred resume every-3-week > recovers chemotherapy administer therapy recommended bone suppression marrow occurrence performed toxicity reaction monitor albumin-bound including protein-bound 100 particles count platelet injectable suspension reduced emboli tachycardia thromboembolism order hypertension late stage mbc thrombosis chemotheraphy treatment for metastatic breast cancer higher 28% treatment for advanced breast cancer 58% adjuvant ischemic supraventricular strokes transient cerebrovascular chest ocular adverse events visual n=366 safety profile dosing modifications 11% dosing administration disturbances clinical trial research infarction grades arrest ischemia important safety information cardiovascular events efficacy 85% 17% constipation dyspnea appetite decreased official observed disease rash rates heart fail failure congestive reports group exhibiting studied relapse months 55% 48% 64% 68% 83% 98% 91% abraxane® epistaxis pneumonia delay abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) 41% pyrexia withholding permanent leading 1-4 retention apprised hazard fetus women woman cycles level fetal harm administered childbearing avoid prior 90% 94% frequently absolute case father child reduce derivative moderate develops withheld &le grade1 modification require dose- schedule-dependent generally weekly doses increased platelets caution starting exposure recover anaphylactic permanently re-challenged 80% 82% substitute infections solution properties rechallenged dose-dependent 31% 33% dose-limiting functional drug’s bilirubin infection neutropenic sepsis elevations mucositis frequent fluid cycle 36% phosphatase abnormal ecg 60% 52% myelotoxicity performing complete symptoms 71% 35% 34% 49% clinical 32% alkaline 44% arthralgia 3-4 studies myalgia dehydration